Table 1 Characteristics of Study Participants.

From: Identification of metabolic biomarkers in patients with type 2 diabetic coronary heart diseases based on metabolomic approach

Variable

HC

CHD

T2DM-CHD

T2DM

N (male/female)

7/8

7/6

15/13

6/9

Age (years)

65.3 ± 6.6

64.7 ± 7.2

67.1 ± 5.8

63.9 ± 7.3

Duration of CHD

0

2.7 ± 4.9

3.4 ± 5.5

0

Duration of T2DM

0

0

5.5 ± 6.2

5.46 ± 4.1

BMI (kg/m2)

25.63 ± 2.04

26.02 ± 2.63

26.31 ± 2.62

24.98 ± 2.93

SBP (mmHg)

121.75 ± 10.65

122 ± 11.46

125.17 ± 12.02

113.64 ± 9.90

DBP (mmHg)

78.66 ± 9.58

75.67 ± 8.63

76.83 ± 11.13

77.10 ± 6.67

Triglycerides (mg/dL)

1.68 ± 0.19

1.95 ± 0.42*

2.12 ± 0.45*

1.34 ± 0.25

LDL (mmol/L)

3.26 ± 0.75

2.75 ± 0.83*

2.68 ± 0.75*

3.05 ± 0.59*

HDL (mmol/L)

1.30 ± 0.32

1.09 ± 0.29*

1.10 ± 0.25*

1.23 ± 0.28

Total cholesterol (mmol/L)

5.39 ± 0.44

6.04 ± 0.55

5.60 ± 0.13

5.74 ± 0.42

BUN (mmol/L)

4.40 ± 1.11

4.91 ± 1.02

5.70 ± 1.22

5.91 ± 1.41

SCr (mmol/L)

69.78 ± 14.04

68.44 ± 9.84

78.20 ± 15.89

65.32 ± 14.39

HbA1c (%)

6.96 ± 0.48

7.63 ± 1.92

8.81 ± 1.34*

8.59 ± 0.32*

FPG (mmol/L)

5.83 ± 1.97

5.34 ± 2.64

10.27 ± 3.29**

8.21 ± 2.94*

2hPG (mmol/L)

7.29 ± 1.24

6.61 ± 0.85

15.01 ± 4.26**

10.53 ± 4.53**

FINS (ulU/ml)

7.91 ± 3.56

8.96 ± 5.74

17.30 ± 9.33**

10.14 ± 6.91*

Medication History

 ACEI or ARB

0 (0)

6 (46.2)

18 (64.3)

0 (0)

 Statins

0 (0)

4 (30.8)

11 (39.3)

0 (0)

 Beta-blocker

0 (0)

5 (38.5)

10 (35.7)

0 (0)

 OHA/insulin

0 (0)

0 (0)

13 (46.4)

3 (20.0)

  1. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low density lipoproteins; HDL: high density lipoproteins; BUN: blood urea nitrogen; SCr: serum creatinine; HbA1c: glycated hemoglobin; FPG: fasting plasma glucose; 2hPG: 2h plasma glucose; FINS: fasting insulin. Data are presented as mean ± SD. *p < 0.05, compared with control group, **p < 0.0001, compared with control group.